India Business News: Indian Immunologicals Ltd (IIL) has rolled out Havisure, India's first indigenous Hepatitis-A vaccine. The vaccine, developed over eight years, is aimed at protecting against the highly contagious liver infection transmitted through contaminated food or water. The two-dose vaccine is suitable for pediatric, adolescent, and adult use. It has undergone extensive clinical trials and has been proven safe and efficacious. The vaccine is priced at Rs 2,150 per dose. IIL has a manufacturing capacity of 1 million doses per year. Havisure is the third vaccine rolled out by IIL in a year's time.
Following the detection of the Omicron variant, one of the most pressing questions today is whether the vaccine will provide protection against the newly detected Covid variant.